Comparing the current results to its competitors, Check Cap Ltd reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Check Cap Ltd's competitors' average revenue growth of 8.94 %, achieved in the same quarter.
Check Cap Ltd's Comment on Competition and Industry Peers
MBody AI operates in a competitive and rapidly changing market where emerging technologies, business models, or new competitors may impact demand for its platform and its market position. The company faces risks related to protecting its intellectual property, including potential litigation and challenges to its patents, which could affect its competitiveness. MBody AI relies on trademark protection to differentiate its products but may encounter risks of rebranding if third parties gain rights to use its trademarks. The company may also face challenges enforcing non-compete agreements, which could allow competitors to benefit from the expertise of former employees. ARC Group International Ltd. is identified as a competitor and is a party to a Purchase Agreement related to the ARC ELOC Facility.
Aclarion Inc is a technology company that operates on a software-as-a-service (SaaS) business model. They provide their customers with cloud-based solutions, enabling them to streamline and automate their business processes efficiently. Aclarion offers a range of customizable software solutions, including data management, project management, and collaboration tools, tailored to meet the specific needs of their clients.
Hologic Incs business model focuses on developing and commercializing medical technologies and diagnostic products, primarily dedicated to womens healthcare. Their offerings include innovative solutions for breast and skeletal health, gynecological health, and surgical products, aiming to improve patient outcomes and enhance healthcare practices.
General Electric Companys business model centers on industrial operations, creating and delivering advanced technologies, products, and services across sectors such as power generation, aviation, healthcare, and renewable energy. The company emphasizes innovation and sustainability, aiming to enhance performance and efficiency for customers while tackling pressing societal and environmental issues.
Exact Sciences Corporation is a medical diagnostics company that specializes in early cancer detection. Their business model involves developing and commercializing non-invasive, DNA-based tests for the detection of colorectal cancer, as well as other cancers and diseases. By leveraging advanced technology and partnerships with healthcare providers, Exact Sciences aims to improve patient outcomes through early detection and intervention.
The Cigna Group operates as a global health service company that provides a diverse array of health insurance products and services. Their business model emphasizes affordable and personalized healthcare solutions for individuals, employers, and governments, with a strong focus on improving health outcomes and overall well-being. To achieve these goals, Cigna collaborates with healthcare providers and partners to ensure quality care, manage costs effectively, and enhance the overall customer experience.
Sources:
Check Cap Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Check Cap Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
